JPS5892613A - 抗悪性腫瘍剤 - Google Patents

抗悪性腫瘍剤

Info

Publication number: JPS5892613A
Authority: JP; Japan
Prior art keywords: compound; composition; drug; animals; acyl
Prior art date: 1981-11-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP57114150A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0457646B2 (de

Inventor

ロランド・ケイ・ロビンス

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

BIRAATETSUKU Inc

Original Assignee

BIRAATETSUKU Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-11-24

Filing date

1982-07-02

Publication date

1983-06-02

1982-07-02 Application filed by BIRAATETSUKU Inc filed Critical BIRAATETSUKU Inc

1983-06-02 Publication of JPS5892613A publication Critical patent/JPS5892613A/ja

1992-09-14 Publication of JPH0457646B2 publication Critical patent/JPH0457646B2/ja

1994-01-14 Priority claimed from JP6002572A external-priority patent/JP2522225B2/ja

Status Granted legal-status Critical Current

Links

230000009876 antimalignant effect Effects 0.000 title 1
230000001173 tumoral effect Effects 0.000 title 1
241001465754 Metazoa Species 0.000 claims description 132
150000001875 compounds Chemical class 0.000 claims description 65
206010028980 Neoplasm Diseases 0.000 claims description 42
238000011282 treatment Methods 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 30
-1 acyl ester derivative of 2-β-D-ribofuranosylthiazole-4-carboxyamide Chemical class 0.000 claims description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
150000002148 esters Chemical class 0.000 claims description 17
201000011510 cancer Diseases 0.000 claims description 16
125000002252 acyl group Chemical group 0.000 claims description 13
238000000034 method Methods 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 11
239000007924 injection Substances 0.000 claims description 10
238000002347 injection Methods 0.000 claims description 10
230000000259 anti-tumor effect Effects 0.000 claims description 9
PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 claims description 7
238000000338 in vitro Methods 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
229910019142 PO4 Inorganic materials 0.000 claims description 5
239000010452 phosphate Substances 0.000 claims description 5
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
150000008064 anhydrides Chemical class 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
239000011541 reaction mixture Substances 0.000 claims description 4
239000005711 Benzoic acid Substances 0.000 claims description 3
235000010233 benzoic acid Nutrition 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000036210 malignancy Effects 0.000 claims description 2
150000001263 acyl chlorides Chemical class 0.000 claims 2
230000002401 inhibitory effect Effects 0.000 claims 2
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims 2
XAZIMCJWLQZWBM-UAKXSSHOSA-N 2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]triazole-4-carboxamide Chemical compound N1=C(C(=O)N)C=NN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XAZIMCJWLQZWBM-UAKXSSHOSA-N 0.000 claims 1
150000007513 acids Chemical class 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
239000003610 charcoal Substances 0.000 claims 1
238000011033 desalting Methods 0.000 claims 1
239000002798 polar solvent Substances 0.000 claims 1
229940079593 drug Drugs 0.000 description 72
239000003814 drug Substances 0.000 description 72
229940125904 compound 1 Drugs 0.000 description 50
238000012360 testing method Methods 0.000 description 39
230000004083 survival effect Effects 0.000 description 28
230000034994 death Effects 0.000 description 26
231100000517 death Toxicity 0.000 description 26
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
210000004027 cell Anatomy 0.000 description 11
239000003937 drug carrier Substances 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 10
206010070863 Toxicity to various agents Diseases 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
230000000840 anti-viral effect Effects 0.000 description 9
229940125782 compound 2 Drugs 0.000 description 9
239000002904 solvent Substances 0.000 description 9
241000699670 Mus sp. Species 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
238000011081 inoculation Methods 0.000 description 7
239000006188 syrup Substances 0.000 description 7
235000020357 syrup Nutrition 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
229940126214 compound 3 Drugs 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000000843 powder Substances 0.000 description 6
238000011160 research Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
229960000329 ribavirin Drugs 0.000 description 5
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
208000028018 Lymphocytic leukaemia Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
229940121363 anti-inflammatory agent Drugs 0.000 description 4
239000002260 anti-inflammatory agent Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000008499 blood brain barrier function Effects 0.000 description 4
210000001218 blood-brain barrier Anatomy 0.000 description 4
239000008101 lactose Substances 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
201000007270 liver cancer Diseases 0.000 description 4
208000014018 liver neoplasm Diseases 0.000 description 4
208000003747 lymphoid leukemia Diseases 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
208000003174 Brain Neoplasms Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000003863 ammonium salts Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
241000709661 Enterovirus Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004353 Polyethylene glycol 8000 Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
206010000269 abscess Diseases 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000005457 ice water Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
150000002736 metal compounds Chemical class 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940085678 polyethylene glycol 8000 Drugs 0.000 description 2
235000019446 polyethylene glycol 8000 Nutrition 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 1
LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
JJSRACWXUSIJFT-UHFFFAOYSA-N 2-(1,3-thiazol-4-yl)acetamide Chemical compound NC(=O)CC1=CSC=N1 JJSRACWXUSIJFT-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
229930091051 Arenine Natural products 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005266 casting Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000004020 conductor Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
125000005131 dialkylammonium group Chemical group 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000003255 drug test Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
238000002513 implantation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000009607 mammography Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
208000037974 severe injury Diseases 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
229940005605 valeric acid Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Landscapes

Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP57114150A 1981-11-24 1982-07-02 抗悪性腫瘍剤 Granted JPS5892613A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US32445581A	1981-11-24	1981-11-24
US324455		1981-11-24
JP6002572A JP2522225B2 (ja)	1994-01-14	1994-01-14	車両用空調装置

Publications (2)

Publication Number	Publication Date
JPS5892613A true JPS5892613A (ja)	1983-06-02
JPH0457646B2 JPH0457646B2 (de)	1992-09-14

Family

ID=26335980

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57114150A Granted JPS5892613A (ja)	1981-11-24	1982-07-02	抗悪性腫瘍剤

Country Status (1)

Country	Link
JP (1)	JPS5892613A (de)

1982
- 1982-07-02 JP JP57114150A patent/JPS5892613A/ja active Granted

Also Published As

Publication number	Publication date
JPH0457646B2 (de)	1992-09-14

Publication	Publication Date	Title
DE69631376T2 (de)	2004-11-11	Substituierte liposaccaride, nützlich in der behandlung und vorbeugung von endotoxemie
DE69822482T2 (de)	2005-03-03	Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
US6586428B2 (en)	2003-07-01	Combined preparations comprising morpholine anthracyclines and anticancer agent
EP0349235A2 (de)	1990-01-03	Niacin und Guar-Mehl enthaltende Zusammensetzung
JPH02304084A (ja)	1990-12-17	抗ウイルス性薬剤
PL193478B1 (pl)	2007-02-28	Środek farmaceutyczny i sposób jego wytwarzania
EP2243486A1 (de)	2010-10-27	Verstärker für adrenomedullin-produktion
JP2007535525A (ja)	2007-12-06	β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
JPH01157995A (ja)	1989-06-21	鎮痛−抗炎症活性を有するガングリオシドの内部エステル
TWI284038B (en)	2007-07-21	Polyhydroxylated benzene-containing compounds
JPS61502055A (ja)	1986-09-18	低減された毒性の薬剤調製物
IL126346A (en)	2004-06-20	Betulinic acid derivatives and pharmaceutical compositions comprising them
US5407924A (en)	1995-04-18	Method of treating pain using inositol triphosphate
DE68919475T2 (de)	1995-05-11	Bivalente liganden, wirksam für die blockierung des enzyms acat.
JPS5892613A (ja)	1983-06-02	抗悪性腫瘍剤
US4680285A (en)	1987-07-14	Treatment of malignant tumors with 2-(β-D-ribofuranosylthiazole-4-carboxamide related compounds
CN104706656B (zh)	2018-07-13	一种用于防治痴呆的天麻提取物或组合物
CA1175421A (en)	1984-10-02	TREATMENT OF MALIGNANT TUMORS WITH 2-.beta.-D- RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE AND RELATED COMPOUNDS
EP1685134B1 (de)	2009-02-11	Neue chelidonin-derivate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen
EP1112066B1 (de)	2003-07-16	Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
US5763419A (en)	1998-06-09	Treatment of malignant tumors with 8-chloroadenosine 3',5'-cyclic monophasphate
WO2005040045A2 (de)	2005-05-06	Verfahren zur herstellung von trans- oder cis-diammoniumdichlorodihydroxoplatin (iv) -salzen und -derivaten und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen
JP4130700B2 (ja)	2008-08-06	抗腫瘍剤含有組成物
JP3779744B2 (ja)	2006-05-31	単糖誘導体または単糖誘導体を含有する脂肪乳剤
JPS58105918A (ja)	1983-06-24	抗悪性腫瘍剤